Chemours Co: Form 10-Q for the period ended Mar 31, 2016
Filed with the SEC on May 9, 2016 and accepted by EDGAR at May 9, 2016, 15:32 ET.
Management's discussion and analysis
As filed, 40,502 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Introduction
Management’s discussion and analysis of our results of operations and financial condition, which we refer to as “MD&A”, supplements the unaudited interim consolidated financial statements included in this quarterly report to help provide an understanding of our financial condition, changes in financial condition and results of our operations. The discussion and analysis presented below refers to and should be read in conjunction with the unaudited interim consolidated financial statements included in this quarterly report, as well as our Annual Report on Form 10-K for the year ended December 31, 2015.
Unless the context otherwise requires, references herein to “The Chemours Company,” “The Chemours Company, LLC,” “Chemours,” "the Company", "our company", “we,” “us,” and “our” refer to The Chemours Company and its consolidated subsidiaries. References herein to “DuPont” refers to E.I. du Pont de Nemours and Company, a Delaware corporation, and its consolidated subsidiaries (other than Chemours and its consolidated subsidiaries), unless the context otherwise requires.
Cautionary Statements About Forward-Looking Statements
This section and other parts of this quarterly report contain forward-looking statements, within the meaning of the federal securities laws, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. The words "believe," "expect," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify “forward-looking statements,” which speak only as of the date the statements were made.
Forward-looking statements are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond Chemours’ control. Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. Factors that could cause or contribute to these differences include those discussed in the "Forward-Looking Statements" and the "Risk Factors" sections in our Annual Report on Form 10-K for the year ended December 31, 2015. The Company assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.
Overview
Chemours is a leading global provider of products that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemical products for markets including plastics and coatings, refrigeration and air conditioning, general industrial, mining and oil refining. Principal products include titanium dioxide, refrigerants, industrial fluoropolymer resins and a portfolio of industrial chemicals including sodium cyanide.
Chemours manages and reports operating results through three reportable segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. Our position with each of these businesses reflects the strong value proposition we provide to our customers based on our long history and reputation in the chemical industry for safety, quality and reliability.
Recent Developments
On April 22, 2016, the Company entered into a Stock and Asset Purchase Agreement (the “Purchase Agreement”) with LANXESS Corporation, (“Lanxess”), pursuant to which Lanxess has agreed to acquire Chemours’ Clean & Disinfect product line (the “C&D Business”) by acquiring certain Chemours' subsidiaries and assets comprising the C&D business for a purchase price of $230 million in cash, subject to customary working capital and other adjustments. The company expects the transaction to close in the second half of 2016. The completion of the transaction is subject to certain customary closing conditions and regulatory approvals.
On March 1, 2016, the Company completed the sale of its aniline facility in Beaumont, Texas to The Dow Chemical Company (Dow) for a cash proceeds of approximately $140 million. As part of this transaction, Chemours also entered into a supply agreement with an initial two-year term to supply Dow with its additional aniline requirements from Chemours' Pascagoula,
Mississippi production facility.
In February 2016, the company and its credit facility lenders entered into an amendment of the existing credit agreement. The amendment changed the leverage ratio covenant to the senior secured net leverage ratio, reduced the minimum levels of interest expense coverage ratio, extended the time during which company can add back benefits of announced cost reduction initiatives on a pro forma basis to consolidated EBITDA (as defined in the credit agreement), increased the amount of pro forma add backs, and reduced the revolver commitment to $750 million.
In January 2016, Chemours and DuPont entered into an agreement, which provided for the extinguishment of payment obligations of cash and working capital true-ups previously contemplated in the separation agreements. As a result, Chemours was not required to make any payments to DuPont, nor did DuPont make any payments to Chemours. In addition, the agreement set forth an advance payment by Dupont of approximately $190 million, which was paid to Chemours in February 2016, for certain specified goods and services that Chemours expects to provide to DuPont over twelve to fifteen months under existing agreements with Chemours. See note 4 to the interim consolidated financial statements for additional information.
Our First Quarter 2016 Results and Business Highlights
Net sales for the three months ended March 31, 2016 were $1.3 billion, a decrease of 5% from $1.4 billion for the three months ended March 31, 2015. We recognized a net income of $51 million for the three months ended March 31, 2016, compared with net income of $43 million for the same period in 2015. Our Adjusted EBITDA was $128 million and $145 million for the three months ended March 31, 2016 and 2015, respectively. Our results for the quarter reflect improvements from Fluoroproducts and Chemical Solutions performance and our cost reduction initiatives, offset by lower sales price in Titanium Technology segment and unfavorable currency impact.
Results of Operations
(Dollars in millions)
| Three months ended March 31, 2016 | 2015 | |
|---|---|---|
| Net sales | $1,297 | $1,363 |
| Cost of goods sold | 1,095 | 1,111 |
| Gross profit | 202 | 252 |
| Selling, general and administrative expense | 133 | 167 |
| Research and development expense | 23 | 23 |
| Employee separation and asset related charges, net | 17 | — |
| Total expenses | 173 | 190 |
| Equity in earnings of affiliates | 5 | 3 |
| Interest expense, net | (57) | — |
| Other income (expense), net | 93 | (7) |
| Income before income taxes | 70 | 58 |
| Provision for income taxes | 19 | 15 |
| Net income | 51 | 43 |
| Less: Net income attributable to noncontrolling interests | — | — |
| Net income attributable to Chemours | $51 | $43 |
Net Sales
Net sales in the first quarter of 2016 were $1.3 billion, a decrease of approximately 5% compared to $1.4 billion in the first quarter of 2015. The decrease in net sales was due to lower selling price of TiO2 and unfavorable impact of foreign currency movements, primarily the Euro against the U.S. dollar. These decreases were offset by higher volumes in Titanium Technology and Chemical Solutions segments.
The table below shows the impact of price, volume, currency and portfolio changes on net sales for the three months ended March 31, 2016 compared with 2015:
(Dollars in millions)
| 2016 Net Sales | Percentage Change vs 2015 | Percentage change due to: Local Price | Volume | Currency Effect | Portfolio/Other | |
|---|---|---|---|---|---|---|
| Worldwide | $1,297 | (5)% | (6)% | 4% | (2)% | (1)% |
Cost of goods sold
Cost of goods sold (COGS) decreased 1% in the three months ended March 31, 2016 in comparison with the same period in 2015. The decrease was driven by lower production costs from lower costs of raw materials, lower overhead costs resulting from the global headcount reduction implemented in the second half of 2015 and portfolio mix, and slightly favorable currency impact of approximately 1%. These decreases were partially offset by increases in sales volumes and approximately $3 million of inventory write-down in the Chemical Solutions segment in the three months ended March 31, 2016 as a result of the previously announced reactive metals solution restructuring. COGS as a percentage of net sales increased by 3% in the three months ended March 31, 2016 in comparison with the same period in 2015 primarily driven by lower average selling prices primarily in TiO2 and unfavorable foreign currency impact on our net sales over our fixed U.S. dollar costs.
Selling, general and administrative expense
Selling, general and administrative (SG&A) expense decreased 20% to $133 million for the three months ended March 31, 2016 when compared to the same period in 2015. This decrease is primarily driven by the cost reduction initiatives implemented during the second of 2015, such as the global workforce reduction and other initiatives in connection with the transformation plan, as well as lower employee benefits. These decreases were partially offset by $5 million of transactions, legal and other related charges incurred in the first quarter of 2016. No similar charges were incurred in the first quarter of 2015. SG&A as a percentage of net sales decreased by 2% due primarily to cost reduction initiatives described above.
Research and development expense
Research and development activities remained flat in comparison to the prior period.
Employee separation and asset-related charges, net
For the three months ended March 31, 2016 , we recorded pre-tax charges of approximately $17 million, for employee separation and other asset-related charges in connection with several restructuring actions initiated in second half of 2015. This cost includes $8 million related to our Edge Moor manufacturing plant decommissioning and dismantling activities in Titanium Technology segment and $4 million related to decommissioning activities of certain production lines in Fluoroproducts segment. We also incurred additional $4 million of employee separation costs due to continued efforts to streamline and simplify our organizational structure and to reduce costs.
Interest expense, net
We incurred interest expense of $57 million for the three months ended March 31, 2016 related to our outstanding long-term debts, including a charge of approximately $4 million to write off a proportionate amount of unamortized debt issuance costs attributable to the reduction in our revolver commitment. There was no comparable expense incurred in the same period in 2015. See Note 14 to our unaudited interim consolidated financial statements for additional information related to our indebtedness.
Other income (expense), net
Other income, net for the three months ended March 31, 2016 primarily includes $89 million of gain recognized from the sale of our aniline facility in Beaumont, Texas to Dow. See Note 6 to the interim consolidated financial statements for additional information related to the sale and component of other income (expense), net.
Provision for income taxes
For the three months ended March 31, 2016, Chemours recorded a tax provision of $19 million with an effective income tax rate of approximately 27%. For the three months ended March 31, 2015, Chemours recorded a tax provision of $15 million with an effective tax rate of approximately 26%. The $4 million increase in the tax provision and slight increase in our effective income tax rate was due primarily to increases in pre-tax income.
Segment Reviews
Adjusted EBITDA represents our primary measure of segment performance and is defined as income (loss) before income taxes excluding the following:
- interest expense, depreciation and amortization,
- non-operating pension and other postretirement employee benefit costs,
- exchange gains (losses),
- employee separation, asset-related charges and other charges, net,
- asset impairments,
- gains (losses) on sale of business or assets, and
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.
A reconciliation of Adjusted EBITDA to net income for the three months ended March 31, 2016 and 2015 is included in Non-GAAP Financial Measures of this Item 2 and in Note 19 to the interim consolidated financial statements.
Titanium Technologies
(Dollars in millions)
| Three months ended March 31, 2016 | 2015 | |
|---|---|---|
| Segment Net Sales | $521 | $545 |
| Adjusted EBITDA | 54 | 93 |
| Adjusted EBITDA Margin | 10% | 17% |
| Change in segment net sales from prior period | Three months ended March 31, 2016 |
|---|---|
| Price | (16)% |
| Volume | 13% |
| Currency | (1)% |
| Portfolio / Other | —% |
| Total change | (4)% |
Segment Net Sales: Net sales decreased by 4% for the three months ended March 31, 2016, compared with the same period in 2015, due primarily to lower selling prices and the continued negative effect of foreign currency primarily against the Euro, Taiwan new dollar and Chinese yuan, while higher volume partially offsets these declines. All regions except China and Latin America experienced higher volumes in the three months ended March 31, 2016 when compared to the same period in 2015. The higher volume in 2016 were in line with seasonal and historical trends, coupled with slight increase in demand from certain of our customers, while 2015 experienced an unusually low volume.
Adjusted EBITDA and Adjusted EBITDA margin: Adjusted EBITDA and Adjusted EBITDA margin decreased during the three months ended March 31, 2016 in comparison with same period in 2015, primarily driven by lower sales and margin due to lower selling price and unfavorable effects of foreign currency. These decreases were partially offset by productivity improvement initiatives, which resulted in lower raw materials and lower plant operating costs, including the impact of the Edge Moor plant shut-down and global headcount reductions implemented in the second half of 2015.
Fluoroproducts
(Dollars in millions)
| Three months ended March 31, 2016 | 2015 | |
|---|---|---|
| Segment Net Sales | $531 | $552 |
| Adjusted EBITDA | 85 | 75 |
| Adjusted EBITDA Margin | 16% | 14% |
| Change in segment net sales from prior period | Three months ended March 31, 2016 |
|---|---|
| Price | 4% |
| Volume | (3)% |
| Currency | (5)% |
| Portfolio / Other | —% |
| Total change | (4)% |
Segment Net Sales: Net sales decreased by 4% for the three months ended March 31, 2016 in comparison with the same period in 2015. Opteon™ refrigerant adoption delivered significant increase in volume over the prior period, along with a higher demand for industrial application fluoropolymer products. These increases, however, were offset by lower volume growth over the prior period due to weaker demand for fluoropolymer products mainly in the consumer electronics industry, phase down of HCFCs refrigerants (i.e., Freon™) as stipulated by the Montreal Protocol and unfavorable foreign currency impact, primarily against the Euro, Brazilian real and Argentine peso among others, resulting in an overall decrease in net sales.
Adjusted EBITDA and Adjusted EBITDA margin: Adjusted EBITDA and Adjusted EBITDA margin increased during the three months ended March 31, 2016 in comparison with same period in 2015. Both increases were primarily due to improved operations of our manufacturing facilities. We incurred approximately $9 million incremental costs in the three months ended March 31, 2015 due to plant outages in our manufacturing facilities that did not recur in 2016. Margin improvement from Opteon™ during the quarter was partially offset by an unfavorable product mix of fluoropolymers.
Chemical Solutions
(Dollars in millions)
| Three months ended March 31, 2016 | 2015 | |
|---|---|---|
| Segment Net Sales | $245 | $266 |
| Adjusted EBITDA | 10 | 1 |
| Adjusted EBITDA Margin | 4% | less than 1% |
| Change in segment net sales from prior period | Three months ended March 31, 2016 |
|---|---|
| Price | (8)% |
| Volume | 3% |
| Currency | (1)% |
| Portfolio / Other | (2)% |
| Total Change | (8)% |
Segment Net Sales: Net sales decreased by 8% in the three months ended March 31, 2016 in comparison with the same period in 2015, primarily due to lower prices resulting from the impact of lower raw materials costs on contractual pass-through terms, portfolio change (i.e. a reduction in aniline sales due to the sale of our Beaumont, Texas facility) and an unfavorable impact of foreign currency exchange rates including the Euro and British pound. These decreases were partially offset by increases in volume across all business units during the three months ended March 31, 2016.
Adjusted EBITDA and Adjusted EBITDA margin: Adjusted EBITDA and Adjusted EBITDA margin increased during the three months ended March 31, 2016 in comparison with same period in 2015. Both increases were driven primarily by the cost reduction efforts, including the global headcount reductions during the second half of 2015 and improvement in plant operating costs.
2016 Outlook
With our transformation plan on track, we expect to reduce structural costs by an additional $200 million in 2016. These cost savings are primarily from actions taken during 2015 including facilities closures, headcount reductions, procurement and productivity enhancements, suspension of 2016 annual salary increases globally, subject to contractual and legal limitations, and suspension of discretionary contribution component in our U.S. 401(k) plan. We anticipate that we will need to establish additional cost reduction initiatives during 2016 to realize our target of reducing structural costs by $350 million through 2017.
For the remainder of 2016, we believe that those cost reductions and our growth initiatives in our transformation plan will help us deliver full year Adjusted EBITDA above our 2015 performance. Along with a reduction in capital spending and strategic steps, we expect to generate modestly positive free cash flow during the year. Our outlook reflects our current visibility and expectations on our strategic actions, market factors, such as currency movements, TiO2 pricing, and end-market demand.
Liquidity & Capital Resources
Chemours' primary source of liquidity is cash generated from operations, available cash and borrowings under the credit facilities as described below. We believe these sources are sufficient to fund our planned operations and to meet our interest, dividend and contractual obligations. Our financial policy seeks to deleverage by using free cash flow to repay outstanding borrowings, selectively invest for growth to enhance our portfolio including certain strategic capital investments, and return cash to shareholders through dividend payments.
Over the next 12 months, Chemours expects to have interest payments, capital expenditures, principal repayments, and restructuring payments. The Company may also use its available cash to reduce its indebtedness and improve its leverage position. We expect to fund these payments through cash generated from operations, asset dispositions, available cash and borrowings under the revolving credit facility. We anticipate that our operations and revolving credit facility will provide sufficient liquidity over the next 12 months. The availability under our Revolving Credit Facility is subject to the last 12 months of our consolidated EBITDA as defined under the credit agreement.
Cash Flow
The following table sets forth a summary of the net cash provided by (used for) operating, investing and financing activities.
(Dollars in millions)
| Three months ended March 31, 2016 | 2015 | |
|---|---|---|
| Cash provided by (used for) operating activities | $36 | $(238) |
| Cash provided by (used for) investing activities | 50 | (159) |
| Cash (used for) provided by financing activities | (16) | 397 |
Operating Activities
Cash provided by operating activities improved by $274 million for the three months ended March 31, 2016 as compared to the same period in 2015 due to working capital improvements and the advance payment of $190 million that we received from DuPont in February 2016, partially offset by interest payments in the first quarter of 2016.
Investing Activities
Cash provided by investing activities for the three months ended March 31, 2016 includes the $140 million proceeds from the sale of our aniline facility in Beaumont, Texas to Dow offset by capital expenditures during the period. Our capital expenditures decreased by approximately $48 million when compared to the same period in 2015 due to lower spend primarily from the near-completion of our Altamira plant expansion and no separation-related expenditures in 2016.
We expect our capital expenditure for 2016 to be less than the 2015 annual spend excluding separation related expenditures.
Financing Activities
In 2015, cash provided by financing activities was primarily from the net cash transfers from DuPont to fund Chemours' capital expenditures and operating activities. There were no significant financing activities during the first quarter of 2016 other than the amendment to our credit facilities described within "Liquidity & Capital Resources - Credit Facilities" of this MD&A.
Current Assets
(Dollars in millions)
| March 31, 2016 | December 31, 2015 | |
|---|---|---|
| Cash | $435 | $366 |
| Accounts and notes receivable - trade, net | 906 | 859 |
| Inventories | 948 | 972 |
| Prepaid expenses and other | 82 | 104 |
| Total current assets | $2,371 | $2,301 |
Accounts and notes receivable - trade, net at March 31, 2016 increased $47 million compared to December 31, 2015 primarily due to timing of collections of trade accounts receivable and favorable currency translation of approximately $8 million.
Inventories at March 31, 2016 decreased $24 million compared to December 31, 2015 due to continued effort to decrease inventory on hand, as well as lower cost of raw materials and production costs, and approximately $3 million of inventory write-down in the Chemical Solutions segment in the three months ended March 31, 2016 as a result of the previously announced reactive metals solution restructuring. These decreases were partially offset by favorable currency translation of approximately $5 million.
Prepaid expenses and other current assets at March 31, 2016 decreased by $22 million compared to December 31, 2015 due to sale of our aniline facility in Beaumont, Texas in February 2016, which was previously classified as assets held-for-sale of approximately $46 million included in this account as of December 31, 2015. This decrease was offset by an increase in prepaid taxes.
Current Liabilities
(Dollars in millions)
| March 31, 2016 | December 31, 2015 | |
|---|---|---|
| Accounts payable | $842 | $973 |
| Short-term borrowings and current maturities of long-term debt | 34 | 39 |
| Other accrued liabilities | 611 | 454 |
| Total current liabilities | $1,487 | $1,466 |
Accounts payable decreased by $131 million compared to December 31, 2015 due to timing of payments to vendors and lower capital expenditures. Other accrued liabilities includes the advance payment we received from DuPont, which was recorded as deferred liability, and approximately $166 million remain outstanding as of March 31, 2016.
Credit Facilities and Notes
In February 2016, an amendment to our credit agreement reduced the total revolver commitment under the revolving credit facility to $750 million beginning in the first quarter of 2016 and revised certain covenants. The proceeds of any loans made under the revolving credit facility can be used to finance capital expenditures, acquisitions, working capital needs and for other general corporate purposes. Availability under the Revolving Credit Facility is subject to certain covenant limitations. At March 31, 2016, the facility has a full borrowing capacity of $750 million. At March 31, 2016, we had $141 million letters of credit issued and outstanding under this facility.
The credit agreement contains financial covenants which, solely with respect to the revolving credit facility as amended, require Chemours not to exceed a maximum senior secured net leverage ratio of 3.50 to 1.00 each quarter through December 31, 2016, 3.00 to 1.00 through June 30, 2017 and further decreasing by 0.25 to 1.00 every subsequent six months to 2.00 to 1.00 by January 1, 2019 and thereafter. Chemours is also required to maintain a minimum interest coverage ratio of 1.75 to 1.00 each quarter through June 30, 2017 and further increasing by 0.25 to 1.00 every subsequent six months to 3.00 to 1.00 by January 1, 2019 and thereafter. In addition, the credit agreement contains customary affirmative and negative covenants that, among other things, limit or restrict Chemours and its subsidiaries' ability, subject to certain exceptions, to incur liens, merge, consolidate or sell, transfer or lease assets, make investments, pay dividends, transact with subsidiaries and incur indebtedness. The credit agreement also contains customary representations and warranties and events of default.
The senior secured credit facilities and the senior unsecured notes contain events of default customary for these types of financings, including cross default and cross acceleration provisions to material indebtedness of Chemours. Chemours was in compliance with its debt covenants as of March 31, 2016.
There are no debt maturities prior to the year 2022, except, in accordance with the credit agreement, Chemours is required to make principal payments related to the Term Loan Facility of $11 million for the remainder of 2016 and $15 million in each year from 2017 to 2021. Debt maturities related to the Term Loan Facility and the Notes in 2022 and beyond will be $3,906 million. In addition, following the end of each fiscal year commencing on the year ended December 31, 2016, Chemours is also required to make additional principal repayment to the Term Loan Facility equivalent to 50% of excess cash flow based on certain leverage targets (as defined in the credit agreement) with stepdowns to 25% and 0% as actual leverage decreases. See Note 14 to the interim consolidated financial statements included in this quarterly report on Form 10-Q for additional information related to our indebtedness.
Supplier Financing
Chemours has entered into a global paying services agreement with a financial institution. Under this agreement, the financial institution acts as the paying agent for Chemours with respect to accounts payable due to our suppliers who elect to participate in the program. The agreement allows our suppliers to sell their receivables to the financial institution at the discretion of both parties on terms that are negotiated between them. Our obligations to our suppliers, including the amounts due and scheduled payment dates, are not impacted by our suppliers' decisions to sell their receivables under this program. At March 31, 2016, the payment instructions from Chemours were $138 million. Pursuant to their agreement with the financial institution, certain suppliers may elect to get paid early at their discretion. The available capacity under this program can vary based on the number of investors participating in this program at any point in time.
Contractual Obligations
Chemours’ contractual obligations at March 31, 2016 did not significantly change from its contractual obligations previously disclosed at December 31, 2015, except in January 2016, Chemours and DuPont entered into an agreement that set forth an advance payment of approximately $190 million for certain specified goods and services to be provide to DuPont over the next twelve to fifteen months under existing agreements with Chemours. See Note 4 to the interim consolidated financial statements included in this quarterly report on Form 10-Q for additional information.
Off Balance Sheet Arrangements
Information with respect to Chemours’ guarantees is included in Note 16 to the unaudited interim consolidated financial statements and in Note 19 to the consolidated financial statements in our Annual Report on Form 10-K. Historically, Chemours has not made significant payments to satisfy guarantee obligations; however, Chemours believes it has the financial resources to satisfy these guarantees in the event required.
Critical Accounting Policies and Estimates
Chemours’ significant accounting policies are described in "Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Estimates" section and Note 3 to the consolidated financial statements in our Annual Report on Form 10-K. There have been no material changes to our critical accounting policies and estimates previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015.
Recent Accounting Pronouncements
See Note 3 to the interim consolidated financial statements included in this quarterly report on Form 10-Q for discussions of recent accounting pronouncements.
Environmental Matters
Environmental Expenses
Environmental expenses charged to current operations include environmental operating costs and the increase in the remediation accrual, if any, during the period reported. As a result of its operations, Chemours incurs costs for pollution abatement activities including waste collection and disposal, installation and maintenance of air pollution controls and wastewater treatment, emissions testing and monitoring and obtaining permits. Chemours also incurs costs for environmental-related research and development activities including environmental field and treatment studies as well as toxicity and degradation testing to evaluate the environmental impact of products and raw materials. Management expects that such expenses in 2016 will be comparable to 2015 and, therefore, does not believe that year over year changes, if any, in environmental expenses charged to current operations will have a material impact on Chemours’ financial position, liquidity or results of operations.
Remediation Accrual
Annual expenditures in the near future are not expected to vary significantly from the range of such expenditures incurred during the past few years. Longer term, expenditures are subject to considerable uncertainty and may fluctuate significantly. There have been no significant changes to the remediation accrual as of March 31, 2016 from December 31, 2015.
As of December 31, 2015, Chemours, through DuPont, has been notified of potential liability under CERCLA or similar state laws at about 174 sites around the U.S., including approximately 22 sites for which Chemours does not believe it has liability based on current information. Active remediation is under way at approximately 53 of these sites. Approximately 66 sites have been resolved either by completing remedial actions with other Potentially Responsible Parties (PRPs) or participating in "de minimis buyouts" with other PRPs whose waste, like Chemours’, represented only a small fraction of the total waste present at a site. No new notices of potential liability at any sites were received during the three months ended March 31, 2016.
At March 31, 2016, we recorded an environmental liability of approximately $293 million relating to these matters which, in management’s opinion, is appropriate based on existing facts and circumstances. The average time-frame over which the accrued or presently unrecognized amounts may be paid, based on past history, is estimated to be 15 to 20 years. Remediation activities vary substantially in duration and cost from site to site. These activities and their associated costs depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of other PRPs. In addition, Chemours, through DuPont, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular there may be considerable variability between the remediation activities that are currently being undertaken or planned, as reflected in the liability recorded at March 31, 2016, and the ultimate actions that could be required.
Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, the potential liability may range up to approximately $600 million above the amount accrued at March 31, 2016. Except for Pompton Lakes, which is discussed further below, based on existing facts and circumstances, management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on the financial position, liquidity or results of operations of Chemours.
Pompton Lakes
The environmental remediation accrual is $86 million as of March 31, 2016 related to activities at Chemours’ site in Pompton Lakes, New Jersey. Management believes that it is reasonably possible that remediation activities at this site could range up to $119 million, including previously accrued amounts. This could have a material impact on the liquidity of Chemours in any given period if recognized. However, management does not believe this would have a material adverse effect on Chemours’ overall financial position, liquidity or results of operations. During the twentieth century, blasting caps, fuses and related materials were manufactured at Pompton Lakes. Operating activities at the site ceased in the mid 1990’s. Primary contaminants in the soil and sediments are lead and mercury. Ground water contaminants include volatile organic compounds.
Under the authority of the Environmental Protection Agency (EPA) and the New Jersey Department of Environmental Protection, remedial actions at the site are focused on investigating and cleaning up the area. Ground water monitoring at the site is ongoing and Chemours, through DuPont, has installed and continues to install vapor mitigation systems at residences within the ground water plume. In addition, Chemours is further assessing ground water conditions. In June 2015, the EPA issued a modification to the site's RCRA permit that requires Chemours to dredge mercury contamination from a 36 acre area of the lake and remove sediment from two other areas of the lake near the shoreline. Chemours expects to spend about $50 million over the next two to three years, which is included in the remediation accrual as of March 31, 2016, in connection with remediation activities at Pompton Lakes, including activities related to the EPA’s proposed plan. The Company expects these activities to begin sometime on or after mid-2016; however initiation of this work in the field is dependent upon timing of agency approval of permits and implementation plans.
PFOA
See discussion under “PFOA” in Note 15 to the interim consolidated financial statements included in this quarterly report on Form 10-Q.
Non-GAAP Financial Measures
We prepare our financial statements in accordance with U.S. GAAP. To supplement our financial information presented in accordance with U.S. GAAP, we provide non-GAAP financial measures (“Adjusted EBITDA”, “Adjusted Net Income” and ”Free Cash Flow”) to provide investors with a better understanding of the Company’s performance when analyzing changes in our underlying business between reporting periods and to allow for greater transparency with respect to supplemental information used by management in its financial and operational decision making. We utilize Adjusted EBITDA as the primary measure of segment profitability used by our Chief Operating Decision Maker (CODM).
Adjusted EBITDA is defined as income (loss) before taxes excluding the following:
- interest expense, depreciation and amortization,
- non-operating pension and other postretirement employee benefit costs,
- exchange gains (losses),
- employee separation, asset-related charges and other charges, net,
- asset impairments,
- gains (losses) on sale of business or assets, and
- other items not considered indicative of our ongoing operational performance and expected to occur infrequently.
Adjusted Net Income (Loss) is defined as net income (loss) attributable to Chemours adjusted for items excluded from Adjusted EBITDA except interest expense, depreciation and amortization, and certain provision for (benefit from) income taxes. Free Cash Flow is defined as cash provided by (used in) operating activities less cash used for purchases of property, plant and equipment as disclosed in the consolidated statements of cash flows (a GAAP financial measures).
We believe the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing the Company’s operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. In the future, we may incur expenses similar to those eliminated in this presentation. Our presentation of Adjusted EBITDA, Adjusted Net Income and Free Cash Flow should not be construed as an inference that our future results will be unaffected by unusual or infrequently occurring items. The non-GAAP financial measures we use may be defined differently from measures with the same or similar names used by other companies. This analysis, as well as the other information provide in this quarterly report on Form 10-Q, should be read in conjunction with the Company’s interim financial statements and notes thereto included in this quarterly report as well as the Company's consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.
The following table reconciles Adjusted EBITDA and Adjusted Net Income discussed above to net income attributable to Chemours for the periods presented:
(Dollars in millions)
| Three months ended March 31, 2016 | 2015 | |
|---|---|---|
| Net income attributable to Chemours | $51 | $43 |
| Non-operating pension and other postretirement employee benefit costs | (7) | 7 |
| Exchange losses | 6 | 16 |
| Restructuring charges | 17 | — |
| Gain on sale of assets or business | (89) | — |
| Transaction, legal and other charges | 8 | — |
| Provision for (benefit from) income taxes relating to reconciling items 1 | 25 | (7) |
| Adjusted Net Income | 11 | 59 |
| Net income attributable to noncontrolling interests | — | — |
| Interest expense, net | 57 | — |
| Depreciation and amortization | 66 | 64 |
| All remaining (benefit from) provision for income taxes 1 | (6) | 22 |
| Adjusted EBITDA | $128 | $145 |
| Weighted average number of common shares outstanding - Basic 2 | 181,281,166 | 180,966,833 |
| Weighted average number of common shares outstanding - Diluted 2 | 181,503,140 | 180,966,833 |
| Earnings per common share, basic | $0.28 | $0.24 |
| Earnings per common share, diluted | $0.28 | $0.24 |
| Adjusted earnings per common share, basic | $0.06 | $0.33 |
| Adjusted earnings per common share, diluted | $0.06 | $0.33 |
1 Total of provision for (benefit from) income taxes reconciles to the amount reported in the unaudited consolidated statement of income for the three months ended March 31, 2016 and 2015.
2 On July 1, 2015, DuPont distributed 180,966,833 shares of Chemours' common stock to holders of its common stock. All earnings per common share amounts for the three months ended March 31, 2015 were calculated using the number of shares distributed on July 1, 2015.
Market risk
As filed, 2,983 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are exposed to changes in foreign currency exchange rates because of our global operations. As a result, we have assets, liabilities and cash flows denominated in a variety of foreign currencies. We are also exposed to changes in the prices of certain commodities that we use in production. Changes in these rates and commodity prices may have an impact on future cash flow and earnings. We manage these risks through normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. We do not enter into derivative financial instruments for trading or speculative purposes.
Chemours enters into foreign currency forward contracts to minimize volatility in earnings related to the foreign exchange gains and losses resulting from remeasuring monetary assets and liabilities that Chemours holds which are denominated in non-functional currencies. These derivatives are stand-alone and have not been designated as a hedge. For the three months ended March 31, 2016, we entered into foreign currency forward contracts and had 40 open contracts with an aggregate notional U.S. dollar equivalent of $270 million, the fair value of which amounted to less than $1 million of net unrealized loss.
In a hypothetical adverse change in the market prices or rates that existed at March 31, 2016, a 10% increase in the U.S. dollar against our outstanding hedged contracts on foreign currencies, such as the Euro, Swiss francs, and Japanese yen, at the currency exchange rates as of March 31, 2016 would increase our net loss by approximately $8 million, while a 10% depreciation of the U.S. Dollar against the same hedged currencies would decrease our net loss by approximately $9 million.
Chemours hedges its net investment in certain European operations. Changes in the fair value of the hedge in the net investment of certain European operations are recorded in accumulated other comprehensive income (loss). For the three months ended March 31, 2016, Chemours did not record any ineffectiveness and recognized a loss of $7 million on its net investment hedges within accumulated other comprehensive income (loss).
Chemours' risk management programs and the underlying exposure are closely correlated, such that the potential loss in value for the risk management portfolio described above would be largely offset by change in the value of the underlying exposure. See Note 16 to the interim consolidated financial statements for further information.
Additional Information
See Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk, of our Annual Report on Form 10-K for the year ended December 31, 2015 for additional information on the Company's utilization of financial instruments and an analysis of the sensitivity of these instruments. There have been no material changes in the market risks previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015.
Controls and procedures
As filed, 1,442 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
The Company maintains a system of disclosure controls and procedures to give reasonable assurance that information required to be disclosed in the Company's reports filed or submitted under the Securities Exchange Act of 1934 (Exchange Act) is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission. These controls and procedures also give reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.
As of March 31, 2016, the company's Chief Executive Officer (CEO) and Chief Financial Officer (CFO), together with management, conducted an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Based on that evaluation, the CEO and CFO concluded that these disclosure controls and procedures are effective at the reasonable assurance level described above.
Changes in Internal Control over Financial Reporting
There has been no change in the Company's internal control over financial reporting that occurred during the quarter ended March 31, 2016 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.
Risk factors
As filed, 137 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2016-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Cost of revenue | 3 months2016-01-01 to 2016-03-31 | $1.09bn | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months2016-01-01 to 2016-03-31 | $202.0m | us-gaap:GrossProfit |
| Research and development | 3 months2016-01-01 to 2016-03-31 | $23.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2016-01-01 to 2016-03-31 | $133.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2016-01-01 to 2016-03-31 | $57.0m | us-gaap:InterestExpense |
| Income tax | 3 months2016-01-01 to 2016-03-31 | $19.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2016-01-01 to 2016-03-31 | $51.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2016-01-01 to 2016-03-31 | $0.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2016-01-01 to 2016-03-31 | $0.28 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2016-01-01 to 2016-03-31 | 181,503,140 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2016-01-01 to 2016-03-31 | $36.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2016-01-01 to 2016-03-31 | $89.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months2016-01-01 to 2016-03-31 | $5.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2016-03-31 | $435.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2016-03-31 | $2.37bn | us-gaap:AssetsCurrent |
| Total assets | At period end2016-03-31 | $6.38bn | us-gaap:Assets |
| Current liabilities | At period end2016-03-31 | $1.49bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2016-03-31 | $6.19bn | us-gaap:Liabilities |
| Long-term debt | At period end2016-03-31 | $3.92bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2016-03-31 | $34.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2016-03-31 | $188.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001627223-16-000102. Last ingested by Listed: Nov 5, 2026, 19:57 ET. Listed shows no prices and gives no investment advice.